Comments
Loading...

NeoGenomics Analyst Ratings

NEONASDAQ
Logo brought to you by Benzinga Data
$7.41
0.131.79%
At close: -
$7.41
0.000.00%
After Hours: May 23, 4:00 PM EDT
Consensus Rating1
Buy
Highest Price Target1
$26.00
Lowest Price Target1
$8.50
Consensus Price Target1
$16.18

NeoGenomics Analyst Ratings and Price Targets | NASDAQ:NEO | Benzinga

NeoGenomics Inc has a consensus price target of $16.18 based on the ratings of 16 analysts. The high is $26 issued by Craig-Hallum on May 1, 2024. The low is $8.5 issued by Needham on April 29, 2025. The 3 most-recent analyst ratings were released by Piper Sandler, Morgan Stanley, and Goldman Sachs on May 6, 2025, May 1, 2025, and April 30, 2025, respectively. With an average price target of $10.67 between Piper Sandler, Morgan Stanley, and Goldman Sachs, there's an implied 43.95% upside for NeoGenomics Inc from these most-recent analyst ratings.

Analyst Trends and Forecast
1
1
Dec 24
3
Jan
2
1
Feb
3
1
Apr
1
1
May
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
3.6
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

Piper Sandler
Morgan Stanley
Goldman Sachs
Leerink Partners
Needham

1calculated from analyst ratings

Analyst Ratings for NeoGenomics

Buy NowGet Alert
05/06/2025Buy Now61.94%Piper Sandler
David Westenberg59%
$18 → $12MaintainsOverweightGet Alert
05/01/2025Buy Now34.95%Morgan Stanley
Tejas Savant49%
$17 → $10MaintainsEqual-WeightGet Alert
04/30/2025Buy Now34.95%Goldman Sachs
Matthew Sykes62%
$15 → $10MaintainsBuyGet Alert
04/30/2025Buy Now21.46%Leerink Partners
Puneet Souda56%
$25 → $9DowngradeOutperform → Market PerformGet Alert
04/29/2025Buy Now14.71%Needham
Mike Matson57%
$18 → $8.5MaintainsBuyGet Alert
04/17/2025Buy Now102.43%Goldman Sachs
Matthew Sykes62%
$17 → $15MaintainsBuyGet Alert
02/26/2025Buy Now142.91%Piper Sandler
David Westenberg59%
$21 → $18MaintainsOverweightGet Alert
02/19/2025Buy Now115.92%B of A Securities
Derik De Bruin84%
$19 → $16MaintainsNeutralGet Alert
02/19/2025Buy Now142.91%Needham
Mike Matson57%
$19 → $18MaintainsBuyGet Alert
01/28/2025Buy Now142.91%Goldman Sachs
Matthew Sykes62%
$20 → $18MaintainsBuyGet Alert
01/16/2025Buy Now—Benchmark
Bruce Jackson41%
—ReiteratesHold → HoldGet Alert
01/15/2025Buy Now156.41%Needham
Mike Matson57%
$19 → $19ReiteratesBuy → BuyGet Alert
01/13/2025Buy Now—Benchmark
Bruce Jackson41%
—DowngradeBuy → HoldGet Alert
01/10/2025Buy Now156.41%Needham
Mike Matson57%
$19 → $19ReiteratesBuy → BuyGet Alert
12/13/2024Buy Now156.41%B of A Securities
Derik De Bruin84%
$18 → $19MaintainsNeutralGet Alert
12/10/2024Buy Now196.9%Jefferies
Tycho Peterson82%
→ $22Initiates → BuyGet Alert
11/06/2024Buy Now156.41%Needham
Mike Matson57%
$19 → $19ReiteratesBuy → BuyGet Alert
09/25/2024Buy Now156.41%Needham
Mike Matson57%
$19 → $19ReiteratesBuy → BuyGet Alert
09/24/2024Buy Now142.91%Benchmark
Bruce Jackson41%
$18 → $18ReiteratesBuy → BuyGet Alert
07/30/2024Buy Now156.41%Stephens & Co.
Mason Carrico38%
$19 → $19ReiteratesOverweight → OverweightGet Alert
07/30/2024Buy Now142.91%Benchmark
Bruce Jackson41%
$18 → $18ReiteratesBuy → BuyGet Alert
07/30/2024Buy Now156.41%Needham
Mike Matson57%
$19 → $19ReiteratesBuy → BuyGet Alert
05/02/2024Buy Now183.4%BTIG
Mark Massaro71%
$23 → $21MaintainsBuyGet Alert
05/01/2024Buy Now142.91%Benchmark
Bruce Jackson41%
$18 → $18ReiteratesBuy → BuyGet Alert
05/01/2024Buy Now169.91%TD Cowen
Dan Brennan62%
$21 → $20MaintainsBuyGet Alert
05/01/2024Buy Now250.88%Craig-Hallum
Alex Nowark65%
→ $26Assumes → BuyGet Alert
04/30/2024Buy Now156.41%Needham
Mike Matson57%
$24 → $19MaintainsBuyGet Alert
02/26/2024Buy Now169.91%Piper Sandler
David Westenberg59%
$18 → $20MaintainsOverweightGet Alert
02/22/2024Buy Now156.41%Goldman Sachs
Matthew Sykes62%
$17 → $19MaintainsBuyGet Alert
02/21/2024Buy Now223.89%Needham
Mike Matson57%
$21 → $24MaintainsBuyGet Alert
12/29/2023Buy Now156.41%TD Cowen
Dan Brennan62%
$22 → $19MaintainsOutperformGet Alert
12/29/2023Buy Now183.4%BTIG
Mark Massaro71%
$25 → $21MaintainsBuyGet Alert
12/28/2023Buy Now183.4%Needham
Mike Matson57%
$21 → $21ReiteratesBuy → BuyGet Alert
11/08/2023Buy Now129.42%Morgan Stanley
Tejas Savant49%
$16 → $17MaintainsEqual-WeightGet Alert
11/07/2023Buy Now183.4%Needham
Mike Matson57%
→ $21ReiteratesBuy → BuyGet Alert
10/24/2023Buy Now115.92%Morgan Stanley
Tejas Savant49%
$18 → $16MaintainsEqual-WeightGet Alert
10/23/2023Buy Now129.42%Goldman Sachs
Matthew Sykes62%
$19 → $17MaintainsBuyGet Alert
10/20/2023Buy Now129.42%Goldman Sachs
Matthew Sykes62%
$19 → $17MaintainsBuyGet Alert
10/16/2023Buy Now142.91%Piper Sandler
David Westenberg59%
$23 → $18MaintainsOverweightGet Alert
08/21/2023Buy Now142.91%Stephens & Co.
Jacob Johnson60%
$16 → $18UpgradeEqual-Weight → OverweightGet Alert
08/09/2023Buy Now142.91%Benchmark
Bruce Jackson41%
$20 → $18MaintainsBuyGet Alert
08/09/2023Buy Now142.91%Morgan Stanley
Tejas Savant49%
$19 → $18MaintainsEqual-WeightGet Alert
08/09/2023Buy Now183.4%Needham
Mike Matson57%
→ $21ReiteratesBuy → BuyGet Alert
05/16/2023Buy Now—Raymond James
Andrew Cooper53%
—DowngradeOutperform → Market PerformGet Alert
05/10/2023Buy Now156.41%Morgan Stanley
Tejas Savant49%
$18 → $19MaintainsEqual-WeightGet Alert
05/09/2023Buy Now237.38%BTIG
Mark Massaro71%
→ $25UpgradeNeutral → BuyGet Alert
05/09/2023Buy Now196.9%TD Cowen
Dan Brennan62%
$20 → $22MaintainsOutperformGet Alert
05/09/2023Buy Now183.4%Needham
Mike Matson57%
→ $21Reiterates → BuyGet Alert
04/18/2023Buy Now183.4%Needham
Mike Matson57%
→ $21MaintainsBuyGet Alert
04/11/2023Buy Now129.42%B of A Securities
Derik De Bruin84%
$18 → $17MaintainsNeutralGet Alert
04/05/2023Buy Now183.4%Needham
Mike Matson57%
→ $21Reiterates → BuyGet Alert
03/03/2023Buy Now169.91%Piper Sandler
David Westenberg59%
$18 → $20MaintainsOverweightGet Alert
02/24/2023Buy Now169.91%Cowen & Co.
Dan Brennan62%
$14 → $20MaintainsOutperformGet Alert
02/24/2023Buy Now142.91%Morgan Stanley
Tejas Savant49%
$17 → $18MaintainsEqual-WeightGet Alert
02/24/2023Buy Now169.91%Benchmark
Bruce Jackson41%
→ $20UpgradeHold → BuyGet Alert
02/24/2023Buy Now156.41%Raymond James
Andrew Cooper53%
$12 → $19MaintainsOutperformGet Alert
02/24/2023Buy Now183.4%Needham
Mike Matson57%
$15 → $21MaintainsBuyGet Alert
02/01/2023Buy Now102.43%Needham
Mike Matson57%
→ $15UpgradeHold → BuyGet Alert
11/14/2022Buy Now142.91%Piper Sandler
David Westenberg59%
$19 → $18MaintainsOverweightGet Alert
11/11/2022Buy Now61.94%Raymond James
Andrew Cooper53%
$15 → $12MaintainsOutperformGet Alert
11/09/2022Buy Now129.42%Morgan Stanley
Tejas Savant49%
$18 → $17MaintainsEqual-WeightGet Alert
11/09/2022Buy Now102.43%SVB Leerink
Puneet Souda56%
$12 → $15MaintainsOutperformGet Alert
08/26/2022Buy Now—Benchmark
Bruce Jackson41%
—DowngradeBuy → HoldGet Alert
08/22/2022Buy Now—Needham
Mike Matson57%
—DowngradeBuy → HoldGet Alert
08/17/2022Buy Now156.41%Piper Sandler
David Westenberg59%
$13 → $19MaintainsOverweightGet Alert
08/10/2022Buy Now142.91%Morgan Stanley
Tejas Savant49%
$19 → $18MaintainsEqual-WeightGet Alert
08/10/2022Buy Now169.91%Goldman Sachs
Matthew Sykes62%
$18 → $20MaintainsBuyGet Alert
08/10/2022Buy Now115.92%Needham
Mike Matson57%
$19 → $16MaintainsBuyGet Alert
06/03/2022Buy Now75.44%Piper Sandler
David Westenberg59%
→ $13Initiates → OverweightGet Alert

FAQ

Q

What is the target price for NeoGenomics (NEO) stock?

A

The latest price target for NeoGenomics (NASDAQ:NEO) was reported by Piper Sandler on May 6, 2025. The analyst firm set a price target for $12.00 expecting NEO to rise to within 12 months (a possible 61.94% upside). 22 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for NeoGenomics (NEO)?

A

The latest analyst rating for NeoGenomics (NASDAQ:NEO) was provided by Piper Sandler, and NeoGenomics maintained their overweight rating.

Q

When was the last upgrade for NeoGenomics (NEO)?

A

The last upgrade for NeoGenomics Inc happened on August 21, 2023 when Stephens & Co. raised their price target to $18. Stephens & Co. previously had an equal-weight for NeoGenomics Inc.

Q

When was the last downgrade for NeoGenomics (NEO)?

A

The last downgrade for NeoGenomics Inc happened on April 30, 2025 when Leerink Partners changed their price target from $25 to $9 for NeoGenomics Inc.

Q

When is the next analyst rating going to be posted or updated for NeoGenomics (NEO)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of NeoGenomics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for NeoGenomics was filed on May 6, 2025 so you should expect the next rating to be made available sometime around May 6, 2026.

Q

Is the Analyst Rating NeoGenomics (NEO) correct?

A

While ratings are subjective and will change, the latest NeoGenomics (NEO) rating was a maintained with a price target of $18.00 to $12.00. The current price NeoGenomics (NEO) is trading at is $7.41, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch